MétaCan
Menu
Back to cohort
Record W2282235435

A new brain delivery system for therapeutic molecules to treat brain primary or metastatic tumors

2007· article· en· W2282235435 on OpenAlexaff
Reinhard Gabathuler, Michel Demeule, Christian Ché, Anthony Régina, Richard Béliveau, Jean‐Paul Castaigne

Bibliographic record

VenueMolecular Cancer Therapeutics · 2007
Typearticle
Languageen
FieldMaterials Science
TopicNanoparticle-Based Drug Delivery
Canadian institutionsAngiochem (Canada)Université du Québec à Montréal
Fundersnot available
KeywordsPaclitaxelIn vivoBlood–brain barrierPharmacologyBrain tumorDrug deliveryMedicineP-glycoproteinIn vitroGliomaCytotoxicityMonoclonal antibodyPharmacokineticsParenchymaCancer researchCancerChemistryPathologyImmunologyAntibodyCentral nervous systemDrug resistanceInternal medicineBiologyMultiple drug resistance
DOInot available

Abstract

fetched live from OpenAlex

C99 Background: The blood-brain barrier (BBB) is the rate limiting factor for the penetration of anticancer drugs into the brain. Angiochem has discovered a new peptide based drug delivery technology (AngioPep) that provides a non-invasive and flexible platform for transporting drugs of any size to the brain. The small molecule of paclitaxel is impeded to reach its target in the brain by the presence of the BBB’s P-glycoprotein (P-gp) efflux pump; therapeutic monoclonal antibodies (MAbs) do not cross the BBB because of their size and hydrophilicity. They have been conjugated to AngioPep to create paclitaxel-AngioPep (ANG1005) and MAb-AngioPep (ANGMAb). They then have been assessed in vitro and in-vivo using different experimental approaches. Material and methods: An in vitro model of the BBB and in situ brain perfusion were used to assess the brain uptake. Distribution, Pharmacokinetic and Toxicity studies were done in rodents and dogs. Efficacy was assessed using xenograft models of glioblastoma (U87) and non-small cell lung carcinoma (NCI-H460) by subcutaneous and intracranial stereotaxic implantation in immunodeficient mice nu/nu. Results: ANG1005: We demonstrate that ANG 1005 is actively transported across the BBB and bypasses the P-gp driven efflux pump leading to a high concentration of paclitaxel in the brain parenchyma. ANG1005 levels in the brain and brain tumors were quantified by LC-MS. In vitro cytotoxicity is comparable to Paclitaxel. In vivo efficacy studies confirm that this vector platform technology delivers a therapeutic amount of paclitaxel to the brain and the tumors. Furthermore the tolerability of ANG-1005 is better than paclitaxel. ANGMAb: Using the in-vitro BBB model and in-situ brain perfusion assay, we show that MAbs are very efficiently transcytosed leading to a high concentration of MAb in the brain parenchyma. In vivo pharmacology studies are on-going to demonstrate therapeutic efficacy. Conclusion: Overall, chemical conjugation of AngioPep to compounds such as small hydrophobic chemotherapeutics (paclitaxel) and larger hydrophilic drugs (MAbs) allow access to the brain parenchyma and reach therapeutic levels for the treatment of brain cancers (primary and secondary brain tumors).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.291
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2007
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicNanoparticle-Based Drug DeliveryFrench-language works237,207